FDA approves dupilumab, injectible biologic, for eosinophilic asthma
www.pulmccm.org
The US Food and Drug Administration (FDA) approved dupilumab (Dupixent, Sanofi/Regeneron) as "add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma," according to the manufacturer's news release.
FDA approves dupilumab, injectible biologic, for eosinophilic asthma
FDA approves dupilumab, injectible biologic…
FDA approves dupilumab, injectible biologic, for eosinophilic asthma
The US Food and Drug Administration (FDA) approved dupilumab (Dupixent, Sanofi/Regeneron) as "add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma," according to the manufacturer's news release.
Comments on this post are for paid subscribers